Диссертация (1140309), страница 19
Текст из файла (страница 19)
ThePREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease forEnzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistantProstate Cancer // Eur Urol. 2016.46.Fizazi K. Does Gleason score (GS) predict efficacy of abiraterone acetate(AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer(mCRPC)? // J. Clin. Oncol. 2014.
Т. 32. — Р. Suppl. 4, Abstr. 20.47.Fizazi K., Higano C.S., Nelson J.B., Gleave M., Miller K., Morris T.,Nathan F.E., McIntosh S., Pemberton K., Moul J.W. Phase III, randomized, placebocontrolled study of docetaxel in combination with zibotentan in patients with metastaticcastration-resistant prostate cancer // J Clin Oncol. 2013. Т.
31. № 14. — Р. 1740-7.48.Fizazi K., Scher H.I., Molina A., Logothetis C.J., Chi K.N., Jones R.J.,Staffurth J.N., North S., Vogelzang N.J., Saad F., Mainwaring P., Harland S., GoodmanO.B., Jr., Sternberg C.N., Li J.H., Kheoh T., Haqq C.M., de Bono J.S., Investigators C.A.-. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:110final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study // Lancet Oncol. 2012. Т. 13. № 10. — Р. 983-92.49.Freedman L.S.
Confidence intervals and statistical power of the‘Validation’ ratio for surrogate or intermediate endpoints // Journal of StatisticalPlanning and Inference. 2001. Т. 100. № 2. — Р. 443.50.Giacinti S., Carlini P., Roberto M., Bassanelli M., Strigari L., Pavese F.,Aschelter A.M., Felici A., Valeriani M., Cognetti F., Marchetti P. Duration of responseto first androgen deprivation therapy, time to castration resistance prostate cancer, andoutcome of metastatic castration resistance prostate cancer patients treated withabiraterone acetate // Anticancer Drugs. 2017. Т. 28. № 1.
— Р. 110-115.51.Glauser M., Pizzo P., Saunders W. Management of Infections inImmunocompromised Patients // 2000. — Р. 471.52.Gleave M.E., Miayake H., Goldie J., Nelson C., Tolcher A. Targeting bcl-2gene to delay androgen-independent progression and enhance chemosensitivity inprostate cancer using antisense bcl-2 oligodeoxynucleotides // Urology. 1999.
Т. 54. №6A Suppl. — Р. 36-46.53.Goodman O.B., Jr., Flaig T.W., Molina A., Mulders P.F., Fizazi K.,Suttmann H., Li J., Kheoh T., de Bono J.S., Scher H.I. Exploratory analysis of thevisceral disease subgroup in a phase III study of abiraterone acetate in metastaticcastration-resistant prostate cancer // Prostate Cancer Prostatic Dis. 2014. Т. 17. № 1.
—Р. 34-9.54.Hague C., Logue J.P. Clinical experience with radium-223 in the treatmentof patients with advanced castrate-resistant prostate cancer and symptomatic bonemetastases // Ther Adv Urol. 2016. Т. 8. № 3. — Р. 175-80.55.Halabi S., Armstrong A.J., Sartor O., de Bono J., Kaplan E., Lin C.Y.,Solomon N.C., Small E.J. Prostate-specific antigen changes as surrogate for overallsurvival in men with metastatic castration-resistant prostate cancer treated with secondline chemotherapy // J Clin Oncol. 2013.
Т. 31. № 31. — Р. 3944-50.56.Halabi S., Lin C.Y., Kelly W.K., Fizazi K.S., Moul J.W., Kaplan E.B.,Morris M.J., Small E.J. Updated prognostic model for predicting overall survival in111first-line chemotherapy for patients with metastatic castration-resistant prostate cancer //J Clin Oncol. 2014. Т. 32.
№ 7. — Р. 671-7.57.Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., DawsonN.A., Levine E.G., Blumenstein B.A., Vogelzang N.J. Prognostic model for predictingsurvival in men with hormone-refractory metastatic prostate cancer // J Clin Oncol.2003.
Т. 21. № 7. — Р. 1232-7.58.Henriksen G., Breistol K., Bruland O.S., Fodstad O., Larsen R.H.Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Rademonstrated in an experimental skeletal metastases model // Cancer Res. 2002. Т. 62.№ 11. — Р. 3120-5.59.Hollstein M., Sidransky D., Vogelstein B., Harris C.C.
p53 mutations inhuman cancers // Science. 1991. Т. 253. № 5015. — Р. 49-53.60.Horwich A., Parker C., de Reijke T., Kataja V., Group E.G.W. Prostatecancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up //Ann Oncol. 2013. Т. 24 Suppl 6. — Р. vi106-14.61.Hussain M., Wolf M., Marshall E., Crawford E.D., Eisenberger M. Effectsof continued androgen-deprivation therapy and other prognostic factors on response andsurvival in phase II chemotherapy trials for hormone-refractory prostate cancer: aSouthwest Oncology Group report // J Clin Oncol.
1994. Т. 12. № 9. — Р. 1868-75.62.Hussain M.H., Pienta K.J., Redman B.G., Cummings G.D., Flaherty L.E.Oral etoposide in the treatment of hormone-refractory prostate cancer // Cancer. 1994.Т. 74. № 1. — Р. 100-3.63.Isaacs J.T. The biology of hormone refractory prostate cancer. Why does itdevelop? // Urol Clin North Am. 1999. Т.
26. № 2. — Р. 263-273.64.Johns W.D., Garnick M.B., Kaplan W.D. Leuprolide therapy for prostatecancer. An association with scintigraphic "flare" on bone scan // Clin Nucl Med. 1990.Т. 15. № 7. — Р. 485-7.65.Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., PensonD.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W.,112Schellhammer P.F., Investigators I.S. Sipuleucel-T immunotherapy for castrationresistant prostate cancer // N Engl J Med. 2010.
Т. 363. № 5. — Р. 411-22.66.Kelly W.K., Halabi S., Carducci M., George D., Mahoney J.F., StadlerW.M., Morris M., Kantoff P., Monk J.P., Kaplan E., Vogelzang N.J., Small E.J.Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel andprednisone with or without bevacizumab in men with metastatic castration-resistantprostate cancer: CALGB 90401 // J Clin Oncol. 2012. Т. 30. № 13. — Р. 1534-40.67.Kelly W.K., Scher H.I. Prostate specific antigen decline after antiandrogenwithdrawal: the flutamide withdrawal syndrome // J Urol. 1993.
Т. 149. № 3. — Р. 607-9.68.Kim K.B., Jo J.K., Ahn S., Lee S., Jeong S.J., Hong S.K., Byun S.S., LeeS.E. Clinical effect of abiraterone acetate in Korean patients with metastatic castrationresistant prostate cancer according to duration of androgen deprivation therapy //Korean J Urol. 2015. Т. 56. № 8. — Р. 580-6.69.Koivisto P.A., Rantala I. Amplification of the androgen receptor gene isassociated with P53 mutation in hormone-refractory recurrent prostate cancer // JPathol.
1999. Т. 187. № 2. — Р. 237-41.70.Kraus L.A., Samuel S.K., Schmid S.M., Dykes D.J., Waud W.R., BisseryM.C. The mechanism of action of docetaxel (Taxotere) in xenograft models is notlimited to bcl-2 phosphorylation // Invest New Drugs. 2003. Т. 21. № 3. — Р. 259-68.71.Kreis W., Budman D.R., Calabro A.
Unique synergism or antagonism ofcombinations of chemotherapeutic and hormonal agents in human prostate cancer celllines // Br J Urol. 1997. Т. 79. № 2. — Р. 196-202.72.Kvale R., Moller B., Wahlqvist R., Fossa S.D., Berner A., Busch C.,Kyrdalen A.E., Svindland A., Viset T., Halvorsen O.J. Concordance between Gleasonscores of needle biopsies and radical prostatectomy specimens: a population-basedstudy // BJU Int. 2009. Т. 103. № 12.
— Р. 1647-54.73.Lane D.P., Benchimol S. p53: oncogene or anti-oncogene? // Genes Dev.1990. Т. 4. № 1. — Р. 1-8.74.Leuprolide Study G. Leuprolide versus diethylstilbestrol for metastaticprostate cancer // N Engl J Med. 1984. Т. 311. № 20. — Р. 1281-6.11375.Lin D.Y., Fleming T.R., De Gruttola V. Estimating the proportion oftreatment effect explained by a surrogate marker // Stat Med. 1997. Т. 16.
№ 13. — Р.1515-27.76.Liu W., Xie C.C., Zhu Y., Li T., Sun J., Cheng Y., Ewing C.M., DalrympleS., Turner A.R., Sun J., Isaacs J.T., Chang B.L., Zheng S.L., Isaacs W.B., Xu J.Homozygous deletions and recurrent amplifications implicate new genes involved inprostate cancer // Neoplasia. 2008.
Т. 10. № 8. — Р. 897-907.77.Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A.,Ettinger S.L., Gleave M.E., Nelson C.C. Androgen levels increase by intratumoral denovo steroidogenesis during progression of castration-resistant prostate cancer // CancerRes. 2008. Т. 68. № 15. — Р. 6407-15.78.Loriot Y., Eymard J.C., Patrikidou A., Ileana E., Massard C., Albiges L.,Di Palma M., Escudier B., Fizazi K. Prior long response to androgen deprivationpredicts response to next-generation androgen receptor axis targeted drugs in castrationresistant prostate cancer // Eur J Cancer.
2015. Т. 51. № 14. — Р. 1946-52.79.Makridakis N.M., di Salle E., Reichardt J.K. Biochemical andpharmacogenetic dissection of human steroid 5 alpha-reductase type II //Pharmacogenetics. 2000. Т. 10. № 5. — Р. 407-13.80.Maughan B.L., Xhou X.C., Suzman D.L., Nadal R., Bassi S., SchweizerM.T., Antonarakis E.S. Optimal sequencing of docetaxel and abiraterone in men withmetastatic castration-resistant prostate cancer // Prostate.
2015. Т. 75. № 15. — Р. 181420.81.Meyers F.J., Gumerlock P.H., Chi S.G., Borchers H., Deitch A.D., deVereWhite R.W. Very frequent p53 mutations in metastatic prostate carcinoma and inmatched primary tumors // Cancer. 1998. Т. 83. № 12. — Р. 2534-9.82.Morant R., Bernhard J., Maibach R., Borner M., Fey M.F., Thurlimann B.,Jacky E., Trinkler F., Bauer J., Zulian G., Hanselmann S., Hurny C., Hering F.Response and palliation in a phase II trial of gemcitabine in hormone-refractorymetastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK) //Ann Oncol.
2000. Т. 11. № 2. — Р. 183-8.11483.Mostaghel E.A. Abiraterone in the treatment of metastatic castration-resistant prostate cancer // Cancer Manag Res. 2014. Т. 6. — Р. 39-51.84.Mulders P.F., Molina A., Marberger M., Saad F., Higano C.S., Chi K.N., LiJ., Kheoh T., Haqq C.M., Fizazi K. Efficacy and safety of abiraterone acetate in anelderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostatecancer after docetaxel-based chemotherapy // Eur Urol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
